J. Boyd

Marie Joseph, Douglas A Levine, Dimitrios Spentzos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Douglas A Levine, Dimitrios Spentzos, H. Otu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implication of snoRNA U50 in human breast cancer.

Wei Zhou, J. Boyd, W. Zhou, 2009, Journal of genetics and genomics = Yi chuan xue bao.

Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair

T. Kunkel, A. Berchuck, J. Boyd, 1996, Nature Genetics.

A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Laurent Ozbun, Douglas A Levine, J Carl Barrett, 2008, Cancer research.

Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers

K. Offit, J. Boyd, M. Robson, 2004, Cancer Research.

The APC I1307K allele and BRCA-associated ovarian cancer risk.

J. Boyd, Y. Sonoda, M. Federici, 1999, American journal of human genetics.

BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer

J. Boyd, S. Narod, J. Kotsopoulos, 2017, International Journal of Gynecologic Cancer.

Evaluation of germline PTEN mutations in endometrial cancer patients.

K. Offit, J. Boyd, R. Barakat, 2005, Gynecologic oncology.

Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.

K. Offit, J. Boyd, P. Saigo, 1998, Cancer research.

The p53 tumor suppressor gene frequently is altered in gynecologic cancers

R. Bast, A. Berchuck, J. Boyd, 1994, American journal of obstetrics and gynecology.

The p53 tumor suppressor gene frequently is altered in gynecologic cancers.

R. Bast, A. Berchuck, J. Boyd, 1994 .

Mutations of the BRCA2 gene in ovarian carcinomas.

F. Couch, M. Morgan, B. Weber, 1996, Cancer research.

Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines

A. Berchuck, J. Boyd, D. Beach, 1996, Molecular carcinogenesis.

Mutations of the Ki-ras oncogene in endometrial carcinoma.

A. Berchuck, J. Boyd, J. McLachlan, 1992, American journal of obstetrics and gynecology.

Suppression of endometrial carcinoma cell tumorigenicity by human chromosome 18

M. Oshimura, J. Boyd, J. Barrett, 1995, Genes, chromosomes & cancer.

Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.

J. Boyd, Y. Sonoda, M. Federici, 2000, Gynecologic oncology.

Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men.

J. Boyd, J. Barrett, W. Allsbrook, 1995, Cancer research.

Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes

K. Offit, J. Boyd, R. Barakat, 2000, Cancer.

Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

J. Boyd, J. Boyd, P. Borgen, 1997, Cancer research.

Molecular genetics of hereditary ovarian cancer.

J. Boyd, 1998, Oncology.

Linked Hereditary Ovarian Cancers BRCA 2 and BRCA 1-Molecular Genetic Characterization of Updated Version

J. Boyd, M. Robson, Kenneth, 2006 .

Hereditary ovarian cancer: molecular genetics and clinical implications.

J. Boyd, S. Rubin, 1997, Gynecologic oncology.

Accuracy of BRCA1 and BRCA2 Founder Mutation Analysis in Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue

K. Offit, J. Boyd, T. Kirchhoff, 2006, Familial Cancer.

INVITED EDITORIAL Inherited Predisposition to Breast and Ovarian Cancer

M. King, J. Boyd, S. Rowell, 2007 .

Special Lecture The Search for '

Elizabeth, J. Boyd, Ming K. Lee, 2006 .

Search For:

M. King, J. Boyd, Ming K. Lee, 2006 .

The search for BRCA1.

M. King, J. Boyd, C. Szabo, 1994, Cancer research.

Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer.

J. Boyd, A. Hummer, J. Shia, 2008, Human pathology.

BRCA1 and BRCA2 Germline Mutations in Lymphoma Patients

J. Satagopan, K. Offit, J. Boyd, 2003, Leukemia & lymphoma.

Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.

P. Humphrey, R. Bast, A. Berchuck, 1993, American journal of obstetrics and gynecology.

Advances in Brief Genetic Instability of Microsatellites in Endometrial Carcinoma

J. Boyd, H. Lynch, Andrew, 2006 .

Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.

J. Boyd, S. Narod, 1999, Journal of the National Cancer Institute.

Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer.

D. Levine, V. Reuter, J. Boyd, 2002, Gynecologic oncology.

Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

M. King, D. Easton, M. Stratton, 1998, American journal of human genetics.

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

A. Berchuck, J. Boyd, J. Barrett, 1995, American journal of obstetrics and gynecology.

Advances in Brief Mutation Analysis of the Putative Tumor Suppressor Gene PTEN / MMAC 1 in Primary Breast Carcinomas

Esther, J. Boyd, Patrick, 2006 .

Dinucleotide repeat polymorphism in the human DCC gene at chromosome 18q21.

J. Boyd, J. Risinger, 1992, Human molecular genetics.

p53 gene mutations in human endometrial carcinoma

J. Boyd, M. Tsao, J. McLachlan, 1992, Molecular carcinogenesis.

Adenovirus-mediated gene therapy of ovarian cancer in a mouse model.

J. Boyd, K. Behbakht, I. Benjamin, 1996, American journal of obstetrics and gynecology.

Lymphocyte subpopulations in mammary cancer after radiotherapy.

J. Boyd, J. M. Anderson, J. Campbell, 1975, Clinical oncology.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance.

A. Horwich, J. Boyd, R. A’Hern, 1991, British Journal of Cancer.

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

M. Morgan, A. Berchuck, B. Weber, 1996, The New England journal of medicine.

Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

A. Lash, D. Levine, J. Boyd, 2005, Clinical Cancer Research.

Mutations of the E–cadherin gene in human gynecologic cancers

A. Berchuck, J. Boyd, M. Kohler, 1994, Nature Genetics.

Resistance to therapy caused by intragenic deletion in BRCA2

Jorge S. Reis-Filho, Alan Ashworth, Christopher J. Lord, 2008, Nature.

Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis

L. Norton, K. Offit, D. Levine, 2007, Annals of Surgical Oncology.

A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.

Hongzhe Li, Yiling Lu, Joel Greshock, 2014, Cancer cell.

Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma

Adam B. Olshen, Mark E. Robson, Kenneth Offit, 2010, PloS one.

Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer

J. Boyd, S. Narod, 2002, Current opinion in obstetrics & gynecology.

BRCA1, BRCA2, and Hereditary Nonpolyposis Colorectal Cancer Gene Mutations in an Unselected Ovarian Cancer Population: Relationship to Family History and Implications for Genetic Testing

T. Rebbeck, J. Boyd, K. Behbakht, 1998 .

Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.

F. Collins, J. Boyd, J. Garber, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome12

N. Schultz, L. Qin, A. Jacobsen, 2015, Neoplasia.

Germline BRCA 1 Mutations and Loss of the Wild-Type Allele in Tumors from Families with Early Onset Breast and Ovarian Cancer 1

F. Collins, B. Weber, J. Boyd, 2005 .

BRCA1-mediated repression of select X chromosome genes

C. Sotiriou, A. Jazaeri, E. Liu, 2004, Journal of Translational Medicine.

Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer

Francis S. Collins, Fergus J. Couch, Barbara L. Weber, 1994, Nature Genetics.

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

J. Boyd, J. Barrett, M. Birrer, 2005, Clinical Cancer Research.

Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management

D. Huntsman, J. Senz, J. Norton, 2005, Clinical Cancer Research.

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

D. Levine, J. Boyd, M. Shah, 2011, Cancer.

Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome

J. Boyd, H. Lynch, P. Borgen, 2004, Breast Cancer Research and Treatment.

Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases

J. Boyd, P. Borgen, S. Kim, 2005, Journal of Medical Genetics.

BRCA Mutations in Women with Ductal Carcinoma In situ

C. Hudis, K. Offit, J. Boyd, 2007, Clinical Cancer Research.

Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.

K. Offit, D. Levine, J. Boyd, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan.

J. Boyd, W. Allsbrook, K. Mangold, 1997, The Journal of urology.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

Use of representational difference analysis for the identification of mdm2 oncogene amplification in diethylstilbestrol‐induced murine uterine adenocarcinomas

J. Boyd, J. Risinger, L. Terry, 1994, Molecular carcinogenesis.

Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability.

T. Kunkel, David C. Thomas, J. Boyd, 1994, The Journal of biological chemistry.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

J. Satagopan, K. Offit, J. Boyd, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genetic instability of microsatellites in endometrial carcinoma.

A. Berchuck, J. Boyd, J. Boyd, 1993, Cancer research.

BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.

T. Rebbeck, J. Boyd, K. Behbakht, 1998, American journal of obstetrics and gynecology.

Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

Javed Khan, Michael J. Birrer, Christos Sotiriou, 2005, Clinical Cancer Research.

Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome

Jingqin Luo, Douglas A Levine, Edwin S Iversen, 2009, Clinical Cancer Research.

Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4‐cM region of chromosome 7q

M. Morgan, A. Berchuck, J. Boyd, 1998, Molecular carcinogenesis.

Risk of endometrial carcinoma associated with BRCA mutation.

J. Satagopan, K. Offit, D. Levine, 2001, Gynecologic oncology.

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

P Borgen, K Offit, J. Satagopan, 1999, Journal of the National Cancer Institute.

Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma.

A. Olshen, A. Viale, J. Boyd, 2004, Gynecologic oncology.

Mutational Analysis of the Estrogen‐Receptor Gene in Endometrial Carcinoma

A. Berchuck, J. Boyd, A. Elbendary, 1995, Obstetrics and gynecology.

Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations

J. Boyd, J. Risinger, 1991, Molecular carcinogenesis.

Comprehensive molecular characterization of clear cell renal cell carcinoma

Steven J. M. Jones, Eric S. Lander, Benjamin J. Raphael, 2013, Nature.

Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma.

M. Morgan, J. Boyd, V. Livolsi, 1997, Cancer Research.

Causes and consequences of microsatellite instability in endometrial carcinoma.

J. Boyd, J. Boyd, M. Federici, 1999, Cancer research.

Causes and Consequences of Microsatellite Instability in Endometrial Carcinoma 1

J. Boyd, M. Federici, L. Kang, 1999 .

Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes.

J. Boyd, 1996, Gynecologic oncology.

Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach.

D. Levine, J. Boyd, M. LaQuaglia, 2005, Gynecologic oncology.

BLM Heterozygosity and the Risk of Colorectal Cancer

P. Gregersen, S. Gruber, J. Satagopan, 2002, Science.

Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers

C. Hudis, K. Offit, J. Boyd, 2005 .

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

J. Satagopan, C. Hudis, L. Norton, 2002, The New England journal of medicine.

The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group.

M. Beckmann, T. Sellers, M. Stratton, 2000, American journal of human genetics.

Origins of ovarian cancer: new insights

J. Boyd, 2011 .

Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.

J. Boyd, Narciso Olvera, M. Leitao, 2004, Gynecologic oncology.

Genetic predisposition to breast cancer: The next chapters

J. Boyd, 2014, Cancer.

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

J. Satagopan, L. Norton, K. Offit, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma

E. Venkatraman, J. Boyd, R. Barakat, 2004, The American journal of surgical pathology.

Fallopian T ube a nd P rimary P eritoneal C arcinomas A ssociated With BRCA Mutations

K. Offit, D. Levine, J. Boyd, 2003 .

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

J. Satagopan, L. Bégin, P. Chappuis, 2003, Breast Cancer Research.

Whole exome sequence analysis of serous borderline tumors of the ovary.

J. Boyd, Hong Wu, S. Peri, 2013, Gynecologic oncology.

Mouse models of gynecologic pathology.

J. Boyd, 2005, The New England journal of medicine.

GATA6 amplification is associated with improved survival of TP53-mutated pancreatic cancer

D. Tuveson, J. Boyd, E. Zhou, 2023, medRxiv.

Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.

A. Jazaeri, J. Boyd, M. Birrer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Classification of ovarian cancer: a genomic analysis.

R. Berkowitz, J. Boyd, M. Birrer, 2008, Advances in experimental medicine and biology.

Incidental MITF, p.E318K Pathogenic Variant in Three Independent Cases Undergoing Hereditary Cancer Risk Assessment

J. Boyd, J. Ordóñez, A. Martir-Negron, 2019 .

Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma.

D. Levine, J. Boyd, R. Barakat, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Profiles of Serous , Endometrioid , and Clear Cell Subtypes ofOvarianand Endometrial Cancer

J. Boyd, J. Barrett, T. Bonome, 2005 .

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

Oscar Lin, J. Boyd, R. Barakat, 2003, Gynecologic oncology.

Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma

L. Bégin, P. Chappuis, W. Foulkes, 2003, Cancer.

Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression Profiles

Adam B. Olshen, A. Olshen, A. Viale, 2005, Clinical Cancer Research.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

Mark E. Robson, Kenneth Offit, Jaya M. Satagopan, 2002 .

p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.

J. Boyd, H. Takahashi, S. Waggoner, 1996, Gynecologic oncology.

ANewRole forER a : SilencingviaDNAMethylation of Basal , Stem Cell , and EMT Genes

J. Boyd, E. Ariazi, M. Slifker, 2017 .

A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes

J. Boyd, E. Ariazi, M. Slifker, 2016, Molecular Cancer Research.

Intraepithelial T cells and tumor proliferation

P. Gimotty, G. Coukos, D. Levine, 2009, Cancer.

The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.

D. Levine, J. Boyd, J. Boyd, 2001, Cancer research.

p53 and genetic susceptibility to cervical cancer.

J. Boyd, Y. Sonoda, P. Saigo, 1999, Journal of the National Cancer Institute.

Genetic basis of familial endometrial cancer: is there more to learn?

J. Boyd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

P. Gregersen, M. King, C. Greenwood, 2002, American journal of human genetics.

Expression and mutational analysis of P53 in stage IB and IIA cervical cancers.

J. Boyd, P. Saigo, H. Takahashi, 1996, American journal of obstetrics and gynecology.

Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer

A. Berchuck, J. Boyd, T. Conrads, 2012, Front. Oncol..

Molecular profiling of endometrial cancers from African-American and Caucasian women.

A. Olshen, A. Viale, D. Levine, 2006, Gynecologic oncology.

Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).

James X. Sun, R. Yelensky, J. Boyd, 2015 .

Risk of Endometrial Carcinoma Associated With BRCA Mutation

J. Satagopan, K. Offit, D. Levine, 2001 .

BRCA Mutations in Womenwith Ductal Carcinoma In situ

C. Hudis, K. Offit, J. Boyd, 2007 .

Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping

Eleazar Eskin, Kenneth Offit, Kirk E Lohmueller, 2008, BMC Genetics.

Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma.

J. Boyd, O. Lin, C. Yee, 2000, Journal of the National Cancer Institute.

Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma.

J. Boyd, 1996, Progress in clinical and biological research.

Comprehensive genomic characterization of squamous cell lung cancers

Joshua M. Stuart, Brian D. O’Connor, Charles J. Vaske, 2012, Nature.

Implication of snoRNA U50 in human breast cancer.

J. Boyd, W. Zhou, P. Guo, 2009, Journal of genetics and genomics = Yi chuan xue bao.